Segment Overview: Jeff Miller, General Manager of the Givosiran program at Alnylam discusses the ENVISION Alnylam Phase 3 trial of its investigational RNAi therapeutic givorsiran for the treatment of acute hepatic porphyrias.
Guest: Jeff Miller
Presenter: Neal Howard
Guest Bio: Mr. Miller joined Alnylam in May 2016 as general manager, with 20 years of experience in the biotechnology and pharmaceutical industry. Prior to joining Alnylam, he held a variety of general management and commercial leadership roles in the United States, Europe, and Canada. While with Alexion, Merck Serono, Boehringer Ingelheim, and Eli Lilly, he worked across many disease areas in Primary Care, Specialty Care, Oncology, and Rare Diseases. Jeff earned his Bachelor of Arts in Communications from the State University of New York at Oswego and his MBA from Boston University